The correlation of the IGF-I, IGFBP-3, and ALS generation test to height velocity after 6 months of recombinant growth hormone therapy in girls with Turner syndrome.
OBJECTIVE
Girls with Turner syndrome (TS) have short stature and benefit from growth hormone therapy (hGH). Some TS present a significant change in height velocity in response to hGH while others have only a mild increment. Our objective was to correlate the response to hGH (height velocity after 6 months of therapy) to biochemical data prior to and after the beginning of hGH to try to define a tool to predict the response to hGH.


METHODS
Thirteen TS participated in the study (ages 3.5-14 years). Levels of IGF-I and IGFBP-3 were measured before and 5, 30 and 90 days after starting hGH (0.05 mg/kg/day), ALS levels were measured only prior and after 5 days.


RESULTS
The mean height velocity (+/-SD) increased from 4.27 (+/-1.18) cm/year to 8.46 (+/-2.17) cm/year (p=0.0001). There was no correlation between the height velocity encountered and the expected height velocity using published mathematical models. Basal ALS values correlated to height velocity SDS and IGF-I and IGFBP-3, after 90 days, correlated to height velocity. Most of the data was too scattered to be used individually for each patient.


CONCLUSIONS
Even though we observed a relationship between biochemical markers and height velocity in TS treated with hGH, the response to hGH therapy in this condition is highly variable.
Collett-Solberg
Paulo F
PF
Department of Endocrinology, Hospital Universitário Clementino Fraga Filho, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Brazil. paulosolberg@yahoo.com
Pessoa de Queiroz
Andréa N
AN
Cardoso
Monique Esteves
ME
Jusan
Rafaela Cattan
RC
Vaisman
Mario
M
Guimarães
Marília M
MM
D000293:Adolescent; D000365:Age Determination by Skeleton; D000367:Age Factors; D001827:Body Height / Q000187:drug effects*; D002352:Carrier Proteins / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005544:Forecasting; D006023:Glycoproteins / Q000097:blood*; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D008137:Longitudinal Studies; D013223:Statistics as Topic; D013997:Time Factors; D014424:Turner Syndrome / Q000097:blood* / Q000188:drug therapy*
D002352:Carrier Proteins; D006023:Glycoproteins; D018972:Insulin-Like Growth Factor Binding Protein 3; C075944:insulin-like growth factor binding protein, acid labile subunit; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I